spacer
home > ict > autumn 2020 > pci pharma services’ game-changing digital platform
PUBLICATIONS
International Clinical Trials

PCI Pharma Services’ Game-Changing Digital Platform

The pharmaceutical industry has historically been risk-averse and slow to adopt technology. PCI Pharma Services is blazing a trail in digitalisation, with everything from real-time supply-chain information, supplier communities, and smart packaging, to virtual audits of their facilities.

“PCI Pharma Services is recognised in the industry as a leader when it comes to providing world-class customer service,” said Wayne Hull, Global Chief Digital and Technology Officer at PCI. “In order to retain that leadership position going forward, digital experiences and capabilities are essential.”

PCI is now a year into its three-year corporate digital transformation strategy that is already differentiating the company, and providing real and measurable returns. Case in point, they recently launched a milestone achievement: an innovative, first of its kind, digital customer platform that will completely transform the customer experience – pci | bridge.

Read full article from PDF >>
Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.
spacer
PCI is committed to supporting clients at every stage of the clinical cycle, delivering best-in-class services efficiently and effectively. Its clients come seeking solutions to often complex and unique opportunities due to its reputation in offering unmatched flexibility, a client-centric experience, and consultative approach, delivering a seamless clinical service including pharmaceutical development, clinical manufacturing, labelling, storage, and distribution. Your bridge between lifechanging therapies and patients.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Northway Biotechpharma and Memo Therapeutics AG collaborate on the fast-track manufacturing of a SARS-CoV-2- neutralizing antibody for the therapy of COVID-19

Vilnius, Lithuania, and Schlieren, Switzerland – August 11, 2020 – Northway Biotechpharma (Northway), a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), and Swiss biotech company Memo Therapeutics AG (MTx), announce a new partnership to manufacture MTx’s therapeutic COVID-19 antibody candidate in a 4-month fast-track process approved by regulatory authorities.
More info >>

White Papers

Extractables and Leachables Testing: A Risk Based Approach

RSSL

Pharmaceutical products are in contact with many external components during both manufacture and usage and small amounts of chemicals may leach from these components with a potential health risk to the patient. Extractables and leachables (E&L) studies therefore play an important role in verifying the safety of a drug product over its lifetime. Regulatory organisations such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) are taking an increased interest in the interactions of various drug delivery devices, pharmaceutical product containers and medical devices with drug product and/or patient and this field is therefore growing in importance. Regulatory guidelines indicate that an extractables profile should be determined for all materials that contact the drug product. Once established, this profile can be used to determine whether any of these extractables are present as leachables within the product. If a leachable is detected, amounts can be determined using validated analytical methods, after which a biological risk can be established based on the exposure. This white paper will provide an overview of the processes used to determine extractables and leachables from plastics.
More info >>

 

 

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page
Send to a friend
Privacy statement